Pfizer, a well-known name in the pharmaceutical world, has grown its business by acquiring companies in different industries. These acquisitions, in areas like biotechnology, cancer treatment, gene therapy, and vaccines, have helped Pfizer strengthen its research and develop new treatments. By expanding into these fields, the company can offer more products, reach new markets, and tackle important healthcare challenges. This shows Pfizer’s ongoing dedication to innovation and improving healthcare for patients around the world.
Notable Acquisitions
1. Seagen (Mar 2023) – Oncology (antibody-drug conjugates for cancer treatment)
2. Global Blood Therapeutics (Aug 2022) – Hematology (treatments for rare blood disorders, particularly sickle cell disease)
3. Biohaven Pharmaceutical (May 2022) – Neurology (CGRP receptor antagonists for migraine treatment)
4. Reviral (Apr 2022) – Infectious Diseases (antiviral therapies)
5. Arena Pharmaceuticals (Dec 2021) – Immunology (therapies for immuno-inflammatory diseases)
6. Trillium Therapeutics (Aug 2021) – Immuno-oncology (cancer treatments targeting the immune system)
7. Array Biopharma (Jun 2019) – Oncology (targeted therapies for colorectal cancer and melanoma)
8. Medivation (Aug 2016) – Oncology (prostate cancer drug, Xtandi)
9. Anacor Pharmaceutical (May 2016) – Dermatology (treatments for eczema and skin conditions)
10. Hospira (Feb 2015) – Biosimilars and Sterile Injectables
For detailed insights, explore Pfizer patent portfolio, and List of Pfizer subsidiaries.
List of Pfizer Acquisitions
| S. No. | Acquiree Name | Price | Announced Date |
| 1 | Seagen | $43B | Mar 13, 2023 |
| 2 | Global Blood Therapeutics | $5.4B | Aug 08, 2022 |
| 3 | Biohaven Pharmaceutical | $11.6B | May 10, 2022 |
| 4 | Resapp Health | $179M | Apr 15, 2022 |
| 5 | Reviral | $525M | Apr 07, 2022 |
| 6 | Arena Pharmaceuticals | $6.7B | Dec 13, 2021 |
| 7 | Trillium Therapeutics | $2.3B | Aug 23, 2021 |
| 8 | Amplyx Pharmaceuticals | – | Apr 28, 2021 |
| 9 | Array Biopharma | $11.4B | Jun 17, 2019 |
| 10 | Therachon | $340M | May 08, 2019 |
| 11 | Medivation | $14B | Aug 22, 2016 |
| 12 | Bamboo Therapeutics | $654M | Aug 01, 2016 |
| 13 | Bind Therapeutics | $40M | Jul 27, 2016 |
| 14 | Anacor Pharmaceutical | $5.2B | May 16, 2016 |
| 15 | Hospira | $15B | Feb 05, 2015 |
| 16 | Redvax | – | Jan 05, 2015 |
| 17 | Baxter International – Marketed Vaccines | $635M | Jul 30, 2014 |
| 18 | Innopharma | $225M | Jul 16, 2014 |
| 19 | Nextwave Pharmaceuticals | $680M | Oct 22, 2012 |
| 20 | Excaliard Pharmaceuticals | – | Nov 22, 2011 |
| 21 | Icagen | $56M | Jul 19, 2011 |
| 22 | King Pharmaceuticals | – | Oct 12, 2010 |
| 23 | Foldrx Pharmaceuticals | – | Sep 01, 2010 |
| 24 | Wyeth Biopharma | – | Oct 01, 2009 |
| 25 | Catapult Genetics | – | Mar 31, 2008 |
| 26 | Serenex | – | Mar 03, 2008 |
| 27 | Encysive Pharmaceuticals | $195M | Feb 20, 2008 |
| 28 | Covx | – | Dec 18, 2007 |
| 29 | Coley Pharmaceutical Group | $164M | Nov 16, 2007 |
| 30 | Biorexis | – | Feb 01, 2007 |
| 31 | Powdermed | – | Oct 09, 2006 |
| 32 | Rinat Neuroscience | – | Apr 07, 2006 |
| 33 | Bioren | – | Aug 15, 2005 |
| 34 | Idun Pharmaceuticals | – | Feb 24, 2005 |
| 35 | Angiosyn | – | Jan 21, 2005 |
| 36 | Esperion | $1.3B | Dec 21, 2003 |
| 37 | Pharmacia | – | Jul 15, 2002 |
| 38 | Warner-Lambert | $90B | Feb 07, 2000 |